1 | 23726675 | A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. | Pain | 2013 Sep |
1 |
2 | 26248047 | The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. | J Clin Pharmacol | 2016 Apr |
5 |
3 | 26317320 | Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. | Br J Clin Pharmacol | 2016 Jan |
2 |
4 | 26535126 | Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. | United European Gastroenterol J | 2015 Oct |
3 |
5 | 26678015 | Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. | J Clin Pharmacol | 2016 Aug |
4 |
6 | 27137716 | Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol. | Clin Pharmacol Drug Dev | 2015 Nov |
1 |
7 | 27299937 | Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling. | CPT Pharmacometrics Syst Pharmacol | 2016 May |
5 |
8 | 27342744 | Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility. | Adv Ther | 2016 Aug |
2 |
9 | 27582887 | The role of naloxegol in the management of opioid-induced bowel dysfunction. | Therap Adv Gastroenterol | 2016 Sep |
2 |
10 | 28035588 | Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist. | Clin Pharmacokinet | 2017 Jun |
1 |
11 | 28336575 | Pharmacologic Profile of Naloxegol, a Peripherally Acting <i>µ</i>-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. | J Pharmacol Exp Ther | 2017 May |
1 |
12 | 33030105 | Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. | J Biomol Struct Dyn | 2022 Mar |
3 |